Carey RM, et al. - Researchers used data from 4,158 participants with hypertension who were taking antihypertensive medication in the 2009 to 2014 National Health and Nutrition Examination Survey in order to compare the prevalence of apparent treatment-resistant hypertension (aTRH) among US adults, as defined in the 2018 and 2008 American Heart Association Scientific Statements. They found that the 2008 and 2018 Scientific Statement definitions demonstrated aTRH prevalence of 17.7% and 19.7%, respectively. Therefore, the use of the definition in the 2018 vs 2008 resulted in only a modestly higher prevalence of aTRH. According to the 2018 Scientific Statement, aTRH was present in 10.3 million US adults. An angiotensin-converting enzyme inhibitor, β-blocker, and thiazide diuretic constituted the most common triple-drug combination therapy. According to the 2018 definition, 3.2% and 9.0% of US adults with aTRH were taking a thiazide-like diuretic (chlorthalidone or indapamide) and a mineralocorticoid receptor blocker (spironolactone or eplerenone), respectively.